IT'S A CLEAR TREATMENT PATH WITH AKEEGA™,THE ONLY FDA-APPROVED DUAL ACTION TABLET
FOR BRCA+ mCRPC

*Niraparib plus abiraterone (combination tablet) is a treatment option for patients with metastatic CRPC and a pathogenic BRCA1 or BRCA2 mutation (germline and/or somatic) who have not yet had treatment in the setting of metastatic CRPC, depending on prior treatment in other disease settings. Use of niraparib/abiraterone for those who have received prior NHT is controversial because a benefit of this combination over use of a PARP inhibitor alone has not been shown in this setting, but responses are likely. The fine particle formulation of abiraterone can be given with single-agent niraparib as a substitute for the combination niraparib/abiraterone tablet (category 2B; other recommended option).²

^†See the NCCN Guidelines^® for detailed recommendations, including other treatment options.²

^‡Continue ADT to maintain castrate levels of serum testosterone (<50 ng/dL).²

^§MAGNITUDE is a phase 3, randomized, double-blind, placebo controlled, multicenter study evaluating treatment with AKEEGA™ vs standard of care (AAP). Cohort 1 consists of 423 subjects with mCRPC and HRR mutations, of which 225 subjects have BRCA mutations, who were randomized (1:1) to receive either AKEEGA™ (n=212) or placebo + AAP once daily (n=211). AKEEGA™ significantly reduced the risk of disease progression or death by 47% [HR = 0.53; 95% CI: 0.36, 0.79; P = 0.0014] in BRCA+ mCRPC patients.^1,3

1L = first-line; AAP = abiraterone acetate (AA) + prednisone (P); ADT = androgen deprivation therapy; BRCA+ = BRCA gene-mutated; CI = confidence interval; HR = hazard ratio; HRR = homologous recombination repair; mCRPC = metastatic castration-resistant prostate cancer; NCCN = National Comprehensive Cancer Network^® (NCCN^®); NHT = novel hormonal therapy; PARP = poly (ADP-ribose) polymerase.